Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Nasal challenge with allergen leads to maxillary sinus inflammation

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Robert M. Naclerio, MD, Jayant Pinto, MD, Fuad Baroody, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Is 9 more than 2 also in allergic airway inflammation?

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fuad M. Baroody, MD, Se-Hoon Suh, MD, Robert M. Naclerio, MD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy Justin M. Skripak, MD, Scott D. Nash, MD, Hannah.

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

The impact of allergic rhinitis on bronchial asthma

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Reply Journal of Allergy and Clinical Immunology

A review of the current guidelines for allergic rhinitis and asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Early decreases in blood eosinophil levels with reslizumab

Phillip Lieberman, MD, David Golden, MD

Ovalbumin content of influenza vaccines

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

What is an “eosinophilic phenotype” of asthma?

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

The Editors' Choice Journal of Allergy and Clinical Immunology

Risk of oral food challenges

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Alvaro A. Cruz, MD, Robert M

Measles and immunomodulation

Nasal challenge with allergen leads to maxillary sinus inflammation

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Safety and efficacy of repeated monthly carboplatin desensitization

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma Philippe Gevaert, MD, PhD, Lien Calus, MD, Thibaut Van Zele,

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis Fuad M. Baroody, MD, David Brown, MD, Laura Gavanescu, MD, Marcy DeTineo, BSN, Robert M. Naclerio, MD Journal of Allergy and Clinical Immunology Volume 127, Issue 4, Pages 927-934 (April 2011) DOI: 10.1016/j.jaci.2011.01.037 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Cumulative nasal congestion score for all 28 days of active therapy. Different treatments are displayed on the x-axis, and individual data are shown with solid bars representing median responses. *P = .003 versus placebo. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Total nasal symptom score (sum of AM and PM scores) during the 4 weeks of active treatment and the 2 weeks after cessation of therapy. The solid vertical line represents cessation of therapy. Data are displayed as medians. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Cumulative total nasal symptom score for all 28 days of active therapy. Different treatments are displayed on the x-axis, and individual data are shown with solid bars representing median responses. *P= .007 versus placebo. †P = .04 versus OXY. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Nasal volume as measured by acoustic rhinometry in mL. The x-axis represents the timeline with baseline measurement and measurements at 2 weeks and 4 weeks of active treatment as well as at 6 weeks after initiation of the study. Treatment was stopped after the 4-week time point as denoted by the solid arrow. *P ≤ .03 versus FF/OXY. †P < .04 versus baseline. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Overall domain of the RQLQ. The x-axis represents the timeline with baseline measurement and measurements at 2 weeks and 4 weeks of active treatment as well as 6 weeks after initiation of the study. Treatment was stopped after the 4-week time point, as denoted by the solid arrow. *P < .02 and †P ≤ .01 versus baseline. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 6 NPIF (sum of AM and PM scores) in liters per minute during the 4 weeks of active treatment and the 2 weeks after cessation of therapy. The solid vertical line represents cessation of therapy. Data are displayed as medians. Journal of Allergy and Clinical Immunology 2011 127, 927-934DOI: (10.1016/j.jaci.2011.01.037) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions